.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Mallinckrodt
Baxter
Cipla
Merck
Colorcon
Covington
Express Scripts
McKinsey

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Clearing of atherosclerosis
Abstract:A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits.
Inventor(s): Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel Simon (Toronto, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Aug 15, 1995
Application Number:08/464,769
Claims:1. A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from the group consisting of hyaluronic acid and its non-toxic salts.

2. The method of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight less than about 750,000 daltons.

3. The method of claim 2 wherein the at least one dosage amount comprising a plurality of dosage amounts administered intravenously at suitable intervals over a period of time.

4. The method of claim 3 wherein the chelating agent is EDTA.

5. The method of claim 3 wherein the NSAID is selected from the group consisting of diclofenac, tromethamine salt of ketoralac, indomethacin, piroxicam, and ibuprofen.

6. The method of claim 3 wherein the anti-oxidant is Vitamin C.

7. The method of claim 2 wherein the at least one such dosage amount comprises

(i) about 1-3 gm of the chelating agent/70 kg person;

(ii) about 15-30 mg of an NSAID;

(iii) about 12-50 gm anti-oxidant; and

(iv) between about 50 mg to well in excess of 1000 mg of the form of hyaluronic acid;

in sterile water.

8. The method of claim 3 wherein the at least one such dosage amount comprises

(i) about 1-3 gm of the chelating agent/70 kg person;

(ii) about 15-30 mg of an NSAID;

(iii) about 12-50 gm anti-oxidant; and

(iv) between about 50 mg to well in excess of 1000 mg of the form of hyaluronic acid;

in sterile water.

9. The method of claim 7 or 8 wherein the chelating agent is EDTA.

10. The method of claim 7 or 8 wherein the NSAID is selected from the group consisting of diclofenac sodium and tromethamine salt of ketoralac.

11. The method of claim 7 or 8 wherein the anti-oxidant is selected from 12.5 to 25 gm of Vitamin C.

12. The method of claim 7 or 8 wherein the amount of sodium hyaluronate exceeds 200 mg.

13. The method of claim 7 or 8 wherein the amount of sodium hyaluronate is about 100 to about 120 mg, and the sodium hyaluronate has a molecular weight of about 150,000-225,000 daltons.

14. The method of claim 7 or 8 wherein the dosage amount further comprises 200 ml of sterile water.

15. The method of claim 7 or 8 wherein the dosage amount further comprises an effective amount of a local anesthetic.

16. The method of claim 15 wherein the dosage amount further comprises an effective amount of bicarbonate of soda.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Queensland Health
Julphar
Cipla
Cerilliant
UBS
Daiichi Sankyo
Healthtrust
McKinsey
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot